Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTCS 46b
说明： GluN1A/GluN2B-selective NMDA antagonist; orally bioavailable
化学名： 1,3-Dihydro-5-[3-[4-(phenylmethyl)-1-2H-benzimidazol-2-one
纯度： ≥98% (HPLC)
生物活性 for TCS 46b
TCS 46b is an orally active, subtype-selective GluN1A/GluN2B (formally NR1A/NR2B) NMDA receptor antagonist (IC50 values are 5.3, 35000 and > 100000 nM for GluN1A/2B (NR1A/2B), GluN1A/2B (NR1A/2B) and GluN1A/2C (NR1A/2C) receptor subtypes respectively). Potentiates the effect of L-DOPA in 6-OHDA-lesioned rats following oral administration.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
技术数据 for TCS 46b
| 分子量 | 345.44 |
| 公式 | C22H23N3O |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 302799-86-6 |
| PubChem ID | 9863010 |
| InChI Key | JJEXWPHPFZLTCU-UHFFFAOYSA-N |
| Smiles | O=C2NC1=CC=C(C#CCN3CCC(CC4=CC=CC=C4)CC3)C=C1N2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for TCS 46b
参考文献 for TCS 46b
参考文献是支持产品生物活性的出版物。
Wright et al (2000) Subtype-selective N-MthD.-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J.Med.Chem. 43 3408 PMID: 10978188
Roger et al (2003) Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer. Bioorg.Med.Chem. 11 5401 PMID: 14642584
按产品操作查看相关产品
关键词: TCS 46b, TCS 46b supplier, Orally, active, subtype-selective, NR1A/NR2B, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, TCS46b, GluN1, GluN2B, 2782, Tocris Bioscience
1 篇 TCS 46b 的引用文献
引用文献是使用了 Tocris 产品的出版物。 TCS 46b 的部分引用包括：
Carlson et al (2012) Pharmacological evidence that D-aspartate activates a current distinct from ionotropic glutamate receptor currents in Aplysia californica. Brain Behav 2 391 PMID: 22950043
TCS 46b 的评论
目前没有该产品的评论。 Be the first to review TCS 46b and earn rewards!
Have you used TCS 46b?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.